New hope for PBC: experimental drug CS0159 enters Mid-Stage trial

NCT ID NCT05896124

Ongoing Disease control Sponsor: Cascade Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a new drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants receive either CS0159 or a placebo for 12 weeks, followed by 40 weeks of open-label treatment. The goal is to see if CS0159 is safe and can lower liver enzyme levels, which are markers of liver damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS0159
What this could lead to: If it works, this could point toward a new treatment option for primary biliary cholangitis, helping control the disease and improve liver function.
What could go wrong: This is an early phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS (PBC)

Contacts and locations

Locations

Beijing Friendship Hospital, Capitai Medical University

Beijing, Beijing Municipality, 100050, China
Beijing Youan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100069, China
Henan Provincial People's Hospital

Zhengzhou, Henan, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Qilu Hospital of Shandong University

Jinan, Shandong, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200120, China
Shaoyifu Hospital of Zhejiang University Medical

Hangzhou, Zhejiang, 310000, China
The Fifth Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangzhou, China
The First Affiliated Hospital of USTC Anhui Provincial Hospital

Hefei, Anhui, 230001, China
The First Affiliated Hospital,Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
The First Bethune Hospital of Jilin University

Changchun, Jilin, China
The Seconed Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China
The Third Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, 510630, China
The Third People's Hospital of Zhenjiang

Zhenjiang, Jiangsu, China
West China Hospital, Sichuan University

Chengdu, Sichuan, China
Wuhan Union Hospital of China

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.